Medgenics, the AIM-listed biopharmaceutical company developing treatments for chronic diseases, has closed an underwritten public offering of 5.6m shares of common stock and Series 2013-A warrants to purchase up to an aggregate of 2.8m shares of common stock.
The shares and the warrants were sold together as a fixed combination, each consisting of one share of common stock and a warrant to purchase one-half of a share of common stock, at a price to the public of $5.25 per fixed combination.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
IFS: Ditch the triple lock and promise never to means-test the state pensionAs part of a blueprint to make us richer in retirement, the Institute for Fiscal Studies is urging the government to reform the state pension and hike pension contributions for high earners
-
‘I transformed my £7,000 pension pot into £420,000 in 20 years after a worrying wake-up call’After spending years neglecting his provisions for retirement, a worrying look into the future prompted a pension saver to take action
